InflaRx presents vilobelimab data

InflaRx (IFRX) announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum were featured in an oral presentation during the late-breaking research abstract session at the 2026 American Academy of Dermatology annual meeting being held March 27-31, 2026, in Denver. The data presented included signals of clinical activity across multiple measures, with higher rates of complete remission, target ulcer closure, and reductions in ulcer volume, as well as a positive safety profile. The primary endpoint, complete target ulcer closure, was achieved by 20.8% of vilobelimab patients versus 16.7% on placebo. Complete disease remission occurred more frequently with vilobelimab than placebo. In addition, over one-third of vilobelimab-treated patients achieved more than a 50% reduction in ulcer volume compared with 16.7% of patients receiving placebo. Physician Global Assessment scores and Dermatology Life Quality Index also showed trends favoring vilobelimab. Vilobelimab treatment also was shown to substantially reduce C5a levels, with mean change from baseline of 76.6% compared to 13.5% with placebo. The treatment was generally well tolerated, with most adverse events reported as mild to moderate and similar rates of serious adverse events between groups.